Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price on Sep 15, 2025
Y-mAbs Therapeutics Revenue
Y-mAbs Therapeutics had revenue of $19.53M in the quarter ending June 30, 2025, a decrease of -14.36%. This brings the company's revenue in the last twelve months to $85.39M, down -1.34% year-over-year. In the year 2024, Y-mAbs Therapeutics had annual revenue of $87.69M with 3.38% growth.
Revenue (ttm)
$85.39M
Revenue Growth
-1.34%
P/S Ratio
4.54
Revenue / Employee
$821,010
Employees
104
Market Cap
391.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 87.69M | 2.87M | 3.38% |
Dec 31, 2023 | 84.82M | 19.55M | 29.96% |
Dec 31, 2022 | 65.27M | 30.37M | 87.03% |
Dec 31, 2021 | 34.90M | 14.15M | 68.18% |
Dec 31, 2020 | 20.75M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionYMAB News
- 2 months ago - Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - GlobeNewsWire
- 2 months ago - Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 2 months ago - Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - Business Wire
- 2 months ago - Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - GlobeNewsWire
- 2 months ago - SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - GlobeNewsWire
- 5 months ago - Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline - GlobeNewsWire
- 5 months ago - Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - GlobeNewsWire
- 5 months ago - Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript - Seeking Alpha